1. China Stocks

  2. •

    Process industries

  3. •

    Chemicals: specialty
CABIO Biotech (Wuhan) Co. Ltd. Class A

CABIO Biotech (Wuhan) Co. Ltd. Class A

SSSE:688089
8.01
CNY
0.00
(0.00%)
1.79BMarket Cap
Oct 30Next Earn
CABIO Biotech (Wuhan) Co. Ltd. Class A
SSE:688089
(Shanghai Stock Exchange)

Recent

price

8.01

P/E

ratio

- -

div

yld

0.23%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.59
1.48
1.46
1.5
1.81
2.28
2.47
1.93
2.09
2.56
2.62
3.31
3.37
- -
Revenue per Share
0.37
0.3
0.16
0.37
0.52
0.77
0.94
0.78
0.76
0.38
0.54
0.74
0.86
- -
Basic EPS, GAAP
0.19
0.2
0.18
0.37
0.61
0.75
0.86
0.67
-0.42
-0.43
-1.35
-0.23
0.75
- -
Free Cash Flow per Basic Share
- -
- -
1.47
0.02
- -
0.29
0.36
0.36
0.24
0.24
0.22
0.2
0.21
0.02
Dividend per Share
3.4
3.7
2.82
3.2
3.7
4.18
7.43
7.84
8.22
8.45
8.77
9.25
9.71
9.1
Book Value per Share
3.21
3.55
2.68
2.99
3.49
3.99
7.35
7.76
8.14
8.23
8.53
8.99
9.45
8.85
Tangible Book Value per Share
126
126
124
126
126
126
126
168
168
169
169
168
167
167
Basic Weighted Avg Shares
200
187
181
190
229
286
312
323
351
433
444
556
563
- -
Sales/Revenue/Turnover
28.02
22.81
12.08
26.42
26.92
31.27
32.73
35.52
29.62
20.8
20.73
23.23
27.23
- -
Operating Margin (%)
29
30
26
27
27
28
29
26
24
27
48
57
62
- -
Depreciation Expense
47
38
20
47
66
97
118
131
129
64
91
124
144
- -
Net Income, GAAP
15.78
12.83
25.54
15.37
15.07
14.03
14.31
14.45
13.66
21.19
13.63
14.08
14.17
- -
Effective Tax Rate (%)
23.34
20.19
10.79
24.74
28.78
33.9
37.93
40.37
36.62
14.85
20.59
22.36
25.52
- -
Profit Margin (%)
192
241
140
192
257
319
1,057
1,071
935
727
596
555
559
546
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
2
2
1
13
50
99
LT Debt
428
466
355
403
464
526
1,250
1,324
1,382
1,425
1,494
1,570
1,644
1,538
Total Equity
- -
8.74
2.82
6.53
9.41
14.01
9.63
8.35
7.54
2.85
4.81
7.12
7.82
- -
Return on Invested Capital (%)
- -
8.48
4.7
11.58
14.6
19.19
13.13
9.81
9.32
4.75
6.54
8.31
9.03
- -
Return on Capital (%)
- -
8.42
4.76
12.38
15.14
19.55
13.32
10.18
9.53
4.6
6.31
8.19
9.01
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
34
100
77
LT Borrowings
50
106
99
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
168
168
168
Market Capitalization
3,918
3,030
1,786

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
722
802
737
Cash, Cash Equivalents & STI
278
387
351
Accounts Receivable, Net
169
125
156
Inventories
173
206
195
Total Current Liabilities
163
213
191
Payables & Accruals
- -
- -
- -
ST Debt
34
100
77
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.76%
4.43%
4.71%
Free Cash Flow
-24.37%
-90.73%
-425.61%
Net Income, GAAP
30.22%
8.42%
15.71%
Sales/Revenue/Turnover
12.4%
12.19%
1.36%
Total Cash Common Dividend
1,208.22%
-8.68%
5.44%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
117
144
126
168
556
2025
156
151
- -
135
563
2026
11
47
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.14
0.26
0.1
0.24
0.74
2025
0.27
0.38
- -
0.09
0.86
2026
-0.26
-0.34
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.2
- -
- -
0.2
2025
- -
- -
- -
0.01
0.21
2026
- -
0.01
- -
- -
- -
Similar Companies
Petkim Petrokimya Holding Anonim Sirketi (BIST:PETKM)
Albemarle Corporation (NYSE:ALB)
Linde plc (NASDAQ:LIN)
Gubre Fabrikalari T.A.S. (BIST:GUBRF)
IOL Chemicals & Pharmaceuticals Ltd. (NSE:IOLCP)
PI Industries Limited (NSE:PIIND)
Business
Cabio Biotech (Wuhan) Co., Ltd. (688089.SS) develops, manufactures and markets high-purity functional ingredients leveraging synthetic biology and microbial fermentation technologies for nutrition, health and personal care applications worldwide; core products include polyunsaturated fatty acids such as arachidonic acid (ARA) and docosahexaenoic acid (DHA), terpenoids including beta-carotene (BC) and astaxanthin, sialic acid (N-acetylneuraminic acid, SA), breast milk oligosaccharides (HMOs, such as NeoHMOs), and innovative bio-based materials like precision fermentation-derived Tastilux for meat-like flavors in alternative proteins; these offerings serve infant formula, health foods, dietary supplements, special medical purpose foods, pet nutrition, economic animal feeds, cosmetics and functional foods, with applications spanning human nutrition, animal nutrition and personal care segments. Founded in September 2004 and headquartered at No. 999 Gaoxin Avenue, Wuhan, Hubei Province, China, the company operates a comprehensive technology platform encompassing microbial strain breeding, cell regulation, separation-purification and high-throughput analysis, supporting global customers primarily in the Asia-Pacific region with expanding international reach; it listed as the first Hubei-based firm on the Shanghai Stock Exchange's Science and Technology Innovation Board in 2019. Recent developments include a November 2024 strategic commercial partnership with Australia's Nourish Ingredients to scale production and commercialization of Tastilux for food ingredients, targeting China and broader Asian markets; a June 2025 merger with Ouyi Biotech to enhance multi-omics technologies for strain optimization and AI-integrated R&D under its "AI + synthetic biology" global strategy; and ongoing advancements in synthetic biology with new laboratory initiatives and product launches like NeoHMOs at international events.